4D Molecular Therapeutics FDMT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$68.76M— | —— | -$56.88M-4.1% | -$54.66M-13.9% | -$47.97M+3.4% | ||
| $1.27M+4.4% | $1.22M-3.6% | $1.26M+8.1% | $1.17M+10.9% | $1.05M-4.1% | ||
| $4.45M-19.8% | $5.55M+22.9% | $4.52M-8.9% | $4.96M-29.0% | $6.99M-7.8% | ||
| -$68.13M— | —— | -$46.5M-7.2% | -$43.38M+9.2% | -$47.76M-4.1% | ||
| $0— | —— | —— | $66K-89.5% | $631K-33.5% | ||
| $68.89M+153% | -$128.85M-825% | $17.78M+228% | -$13.85M-143% | $31.95M— | ||
| $11.48M-89.7% | $111.98M+96,436% | $116K-86.5% | $862K— | $0-100% | ||
| $12.25M— | —— | -$28.6M+49.3% | -$56.37M-257% | -$15.81M+58.6% | ||
| -$68.13M— | —— | -$46.41M-6.8% | -$43.44M+10.2% | -$48.39M-3.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does 4D Molecular Therapeutics generate?
- 4D Molecular Therapeutics (FDMT) generated -$205.8M in operating cash flow over the trailing twelve months.
- What is 4D Molecular Therapeutics's free cash flow?
- After $1.6M of capital expenditures, 4D Molecular Therapeutics's free cash flow was -$206.4M over the trailing twelve months, down 49.1% year over year.
- Where does 4D Molecular Therapeutics's cash flow data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
